Philip Quirke

List of Publications by Year
in descending order

204 papers	26,903 citations	13865 67 h-index	5988 160 g-index
207 all docs	207 docs citations	207 times ranked	18721 citing authors

#	Article	IF	Citations
1	FOCUS4 biomarker laboratories: from the benefits to the practical and logistical issues faced during 6 years of centralised testing. Journal of Clinical Pathology, 2023, 76, 548-554.	2.0	1
2	Weakly supervised annotation–free cancer detection and prediction of genotype in routine histopathology. Journal of Pathology, 2022, 256, 50-60.	4.5	48
3	Improving the management of early colorectal cancers (eCRC) by using quantitative markers to predict lymph node involvement and thus the need for major resection of pT1 cancers. Journal of Clinical Pathology, 2022, 75, 545-550.	2.0	5
4	Deep learning identifies inflamed fat as a risk factor for lymph node metastasis in early colorectal cancer. Journal of Pathology, 2022, 256, 269-281.	4.5	39
5	Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. Clinical Trials, 2022, 19, 146-157.	1.6	7
6	Swarm learning for decentralized artificial intelligence in cancer histopathology. Nature Medicine, 2022, 28, 1232-1239.	30.7	77
7	The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC).. Journal of Clinical Oncology, 2022, 40, 3540-3540.	1.6	0
8	STAR-TREC phase II: Can we save the rectum by watchful waiting or transanal surgery following (chemo)radiotherapy versus total mesorectal excision for early rectal cancer?. Journal of Clinical Oncology, 2022, 40, 3502-3502.	1.6	9
9	Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning. Gut, 2021, 70, 544-554.	12.1	148
10	Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study. The Lancet Gastroenterology and Hepatology, 2021, 6, 92-105.	8.1	90
11	Addressing the variation in adjuvant chemotherapy treatment for colorectal cancer: Can a regional intervention promote national change?. International Journal of Cancer, 2021, 148, 845-856.	5.1	10
12	Artificial intelligence-assisted immunohistochemical (IHC) evaluation of tumor amphiregulin (AREG) and epiregulin (EREG) expression as a combined predictive biomarker for panitumumab (Pan) therapy benefit in RAS wild-type (wt) metastatic colorectal cancer (mCRC): Analysis within the phase III PICCOLO trial.. Journal of Clinical Oncology, 2021, 39, 111-111.	1.6	1
13	Deep learning detects genetic alterations in cancer histology generated by adversarial networks. Journal of Pathology, 2021, 254, 70-79.	4.5	31
14	The colorectal cancer-associated faecal microbiome of developing countries resembles that of developed countries. Genome Medicine, 2021, 13, 27.	8.2	25
15	Microbiome Analysis of More Than 2,000 NHS Bowel Cancer Screening Programme Samples Shows the Potential to Improve Screening Accuracy. Clinical Cancer Research, 2021, 27, 2246-2254.	7.0	18
16	What is the Role of the Neutrophil: Lymphocyte Ratio in Colorectal Cancer?. Turkish Journal of Colorectal Disease, 2021, 31, 1-12.	0.2	2
17	Artificial Intelligence–Assisted Amphiregulin and Epiregulin IHC Predicts Panitumumab Benefit in <i>RAS</i> Wild-Type Metastatic Colorectal Cancer. Clinical Cancer Research, 2021, 27, 3422-3431.	7.0	10
18	Luminal Bioavailability of Orally Administered Ï‰-3 PUFAs in the Distal Small Intestine, and Associated Changes to the Ileal Microbiome, in Humans with a Temporary Ileostomy. Journal of Nutrition, 2021, 151, 2142-2152.	2.9	4

#	Article	IF	Citations
19	Oral maintenance capecitabine versus active monitoring for patients with metastatic colorectal cancer (mCRC) who are stable or responding after 16 weeks of first-line treatment: Results from the randomized FOCUS4-N trial.. Journal of Clinical Oncology, 2021, 39, 3504-3504.	1.6	1
20	Lynch syndrome screening in colorectal cancer: results of a prospective 2‑year regional programme validating the NICE diagnostics guidance pathway throughout a 5.2‑million population. Histopathology, 2021, 79, 690-699.	2.9	9
21	Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone. British Journal of Cancer, 2021, 125, 1080-1088.	6.4	10
22	Characterisation of dysplastic liver nodules using low‑pass <scp>DNA</scp> sequencing and detection of chromosome arm‑level abnormalities in blood‑derived cell‑free <scp>DNA</scp>. Journal of Pathology, 2021, 255, 30-40.	4.5	4
23	Inhibition of WEE1 Is Effective in<i>TP53</i>- and<i>RAS</i>-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring. Journal of Clinical Oncology, 2021, 39, 3705-3715.	1.6	51
24	Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial. Journal of Clinical Oncology, 2021, 39, 3693-3704.	1.6	19
25	Prognostic and Predictive Value of Tumor Budding in Colorectal Cancer. Clinical Colorectal Cancer, 2021, 20, 256-264.	2.3	9
26	Influence of age on surgical treatment and postoperative outcomes of patients with colorectal cancer in Denmark and Yorkshire, England. Colorectal Disease, 2021, 23, 3152-3161.	1.4	7
27	Development and validation of deep learning classifiers to detect Epstein-Barr virus and microsatellite instability status in gastric cancer: a retrospective multicentre cohort study. The Lancet Digital Health, 2021, 3, e654-e664.	12.3	69
28	Quality of Surgery. , 2021, , 279-295.		0
29	Deep learning for the detection of microsatellite instability from histology images in colorectal cancer: A systematic literature review. ImmunoInformatics, 2021, 3-4, 100008.	2.2	21
30	The sigmoid take-off: An anatomical imaging definition of the rectum validated on specimen analysis. European Journal of Surgical Oncology, 2020, 46, 1668-1672.	1.0	20
31	Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia. British Journal of Cancer, 2020, 123, 1280-1288.	6.4	45
32	A robust multiplex immunofluorescence and digital pathology workflow for the characterisation of the tumour immune microenvironment. Molecular Oncology, 2020, 14, 2384-2402.	4.6	71
33	Clinical-Grade Detection of Microsatellite Instability in Colorectal Tumors by Deep Learning. Gastroenterology, 2020, 159, 1406-1416.e11.	1.3	209
34	Mutational signature in colorectal cancer caused by genotoxic pks+ E. coli. Nature, 2020, 580, 269-273.	27.8	587
35	What factors determine specimen quality in colon cancer surgery? A cohort study. International Journal of Colorectal Disease, 2020, 35, 869-880.	2.2	4
36	Outcome measures in multimodal rectal cancer trials. Lancet Oncology, The, 2020, 21, e252-e264.	10.7	56

#	Article	IF	Citations
37	Confirmation that somatic mutations of betaâ€2 microglobulin correlate with a lack of recurrence in a subset of stage II mismatch repair deficient colorectal cancers from the QUASAR trial. Histopathology, 2019, 75, 236-246.	2.9	15
38	Robotic-assisted surgery compared with laparoscopic resection surgery for rectal cancer: the ROLARR RCT. Efficacy and Mechanism Evaluation, 2019, 6, 1-140.	0.7	27
39	No Significant Association Between the Fecal Microbiome and the Presence of Irritable Bowel Syndrome-type Symptoms in Patients with Quiescent Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 1597-1605.	1.9	20
40	Intratumoral stromal morphometry predicts disease recurrence but not response to 5â€fluorouracilâ€"results from the <scp>QUASAR</scp> trial of colorectal cancer. Histopathology, 2018, 72, 391-404.	2.9	16
41	Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer. JAMA Oncology, 2018, 4, 564.	7.1	19
42	A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota. Gut, 2018, 67, 1974-1983.	12.1	332
43	Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS , and NRAS (FOCUS4-D): a phase 2â€"3 randomised trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 162-171.	8.1	47
44	A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS. British Journal of Cancer, 2018, 119, 697-706.	6.4	26
45	Colon cancer surgery: pathological quality control is essential for optimal outcomes. Colorectal Disease, 2018, 20, 34-35.	1.4	5
46	Reply to. Annals of Surgery, 2017, 266, e116-e118.	4.2	1
47	Challenging diagnostic issues in adenomatous polyps with epithelial misplacement in bowel cancer screening: 5 yearsâ€™ experience of the Bowel Cancer Screening Programme Expert Board. Histopathology, 2017, 70, 466-472.	2.9	19
48	Examining the potential use and long-term stability of guaiac faecal occult blood test cards for microbial DNA 16S rRNA sequencing. Journal of Clinical Pathology, 2017, 70, 600-606.	2.0	16
49	Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Modern Pathology, 2017, 30, 1299-1311.	5.5	652
50	Tumor Deposits in Colorectal Cancer: Improving the Value of Modern Stagingâ€"A Systematic Review and Meta-Analysis. Journal of Clinical Oncology, 2017, 35, 1119-1127.	1.6	166
51	Effect of Robotic-Assisted vs Conventional Laparoscopic Surgery on Risk of Conversion to Open Laparotomy Among Patients Undergoing Resection for Rectal Cancer. JAMA - Journal of the American Medical Association, 2017, 318, 1569.	7.4	891
52	Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations. British Journal of Cancer, 2017, 117, 1286-1294.	6.4	22
53	A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial. Trials, 2017, 18, 394.	1.6	72
54	Can we <i>S</i>ave the rectum by watchful waiting or <i>T</i>rans<i>A</i>nal microsurgery following (chemo) <i>R</i>adiotherapy versus <i>T</i>otal mesorectal excision for early <i>RE</i>ctal <i>C</i>ancer (STAR-TREC study)?: protocol for a multicentre, randomised feasibility study. BMJ Open, 2017, 7, e019474.	1.9	87

#	Article	IF	Citations
55	Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer. Oncotarget, 2017, 8, 63140-63154.	1.8	19
56	Identification of 42 Genes Linked to Stage II Colorectal Cancer Metastatic Relapse. International Journal of Molecular Sciences, 2016, 17, 598.	4.1	10
57	Protocol for a multicentre randomised feasibility trial evaluating early Surgery Alone In LOw Rectal cancer (SAILOR). BMJ Open, 2016, 6, e012496.	1.9	4
58	Reply to D.J. Sargent et al. Journal of Clinical Oncology, 2016, 34, 3713-3714.	1.6	0
59	Incorporating Local and Global Context for Better Automated Analysis of Colorectal Cancer on Digital Pathology Slides. Procedia Computer Science, 2016, 90, 125-131.	2.0	7
60	Significant Individual Variation Between Pathologists in the Evaluation of Colon Cancer Specimens After Complete Mesocolic Excision. Diseases of the Colon and Rectum, 2016, 59, 953-961.	1.3	24
61	A retrospective observational study of length of stay in hospital after colorectal cancer surgery in England (1998â€"2010). Medicine (United States), 2016, 95, e5064.	1.0	27
62	Prospective Validation of a Low Rectal Cancer Magnetic Resonance Imaging Staging System and Development of a Local Recurrence Risk Stratification Model. Annals of Surgery, 2016, 263, 751-760.	4.2	243
63	<scp>HER2</scp> overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the <scp>QUASAR</scp>, <scp>FOCUS</scp> and <scp>PICCOLO</scp> colorectal cancer trials. Journal of Pathology, 2016, 238, 562-570.	4.5	185
64	Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With<i>RAS</i>Wild-Type Advanced Colorectal Cancer. JAMA Oncology, 2016, 2, 633.	7.1	79
65	Should the Benefit of Adjuvant Chemotherapy in Colon Cancer Be Re-Evaluated?. Journal of Clinical Oncology, 2016, 34, 1297-1299.	1.6	65
66	The Design and Evaluation of Interfaces for Navigating Gigapixel Images in Digital Pathology. ACM Transactions on Computer-Human Interaction, 2016, 23, 1-29.	5.7	13
67	Clinical Trial of Oral Nelfinavir before and during Radiation Therapy for Advanced Rectal Cancer. Clinical Cancer Research, 2016, 22, 1922-1931.	7.0	30
68	Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial. Journal of Clinical Pathology, 2016, 69, 35-41.	2.0	23
69	Next Generation intraoperative Lymph node staging for Stratified colon cancer surgery (GLiSten): a multicentre, multinational feasibility study of fluorescence in predicting lymph node-positive disease. Efficacy and Mechanism Evaluation, 2016, 3, 1-122.	0.7	3
70	Performance and interaction behaviour during visual search on large, high-resolution displays. Information Visualization, 2015, 14, 137-147.	1.9	12
71	The D Prefix. Diseases of the Colon and Rectum, 2015, 58, 613-616.	1.3	4
72	A Retrospective Observational Study of the Relationship between Single Nucleotide Polymorphisms Associated with the Risk of Developing Colorectal Cancer and Survival. PLoS ONE, 2015, 10, e0117816.	2.5	10

#	Article	IF	Citations
73	Quality of Surgery. , 2015, , 227-242.		0
74	Quality of surgery: has the time come for colon cancer?. Lancet Oncology, The, 2015, 16, 121-122.	10.7	16
75	New insights into the lymphovascular microanatomy of the colon and the risk of metastases in pT1 colorectal cancer obtained with quantitative methods and three‐dimensional digital reconstruction. Histopathology, 2015, 67, 167-175.	2.9	13
76	The correlation between endoscopic and histopathological measurements in colorectal polyps. Histopathology, 2015, 66, 485-490.	2.9	11
77	Cross-laboratory validation of the OncoScanÂ® FFPE Assay, a multiplex tool for whole genome tumour profiling. BMC Medical Genomics, 2015, 8, 5.	1.5	84
78	Early rectal cancer: the European Association for Endoscopic Surgery (EAES) clinical consensus conference. Surgical Endoscopy and Other Interventional Techniques, 2015, 29, 755-773.	2.4	120
79	Area of Submucosal Invasion and Width of Invasion Predicts Lymph Node Metastasis in pT1 Colorectal Cancers. Diseases of the Colon and Rectum, 2015, 58, 393-400.	1.3	62
80	Pathologic Processing of the Total Mesorectal Excision. Clinics in Colon and Rectal Surgery, 2015, 28, 043-052.	1.1	33
81	Secrets from the microbiome: molecular biology meets microbiology meets histopathology‰‰¦ ‰meets clinical biochemistry. Annals of Clinical Biochemistry, 2015, 52, 687-689.	1.6	0
82	Prospector: A web-based tool for rapid acquisition of gold standard data for pathology research and image analysis. Journal of Pathology Informatics, 2015, 6, 21.	1.7	4
83	Reply to C. Zhuang et al. Journal of Clinical Oncology, 2014, 32, 4022-4022.	1.6	2
84	Pathology is a necessary and informative tool in oncology clinical trials. Journal of Pathology, 2014, 232, 185-189.	4.5	17
85	The English National Low Rectal Cancer Development Programme: key messages and future perspectives. Colorectal Disease, 2014, 16, 173-178.	1.4	61
86	Quality of Surgery for Stage III Colon Cancer: Comparison Between England, Germany, and Japan. Annals of Surgical Oncology, 2014, 21, 398-404.	1.5	74
87	EURECCA colorectal: Multidisciplinary management: European consensus conference colon & rectum. European Journal of Cancer, 2014, 50, 1.e1-1.e34.	2.8	349
88	Preoperative Magnetic Resonance Imaging Assessment of Circumferential Resection Margin Predicts Disease-Free Survival and Local Recurrence: 5-Year Follow-Up Results of the MERCURY Study. Journal of Clinical Oncology, 2014, 32, 34-43.	1.6	477
89	Response. Journal of the National Cancer Institute, 2014, 106, .	6.3	0
90	Multicenter Randomized Controlled Trial of Conventional Versus Laparoscopic Surgery for Colorectal Cancer Within an Enhanced Recovery Programme: EnROL. Journal of Clinical Oncology, 2014, 32, 1804-1811.	1.6	170

#	Article	IF	Citations
91	Detection of somatic mutations in tumors using unaligned clonal sequencing data. Laboratory Investigation, 2014, 94, 1173-1183.	3.7	2
92	Mismatch Repair Status and *BRAF* Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies. Clinical Cancer Research, 2014, 20, 5322-5330.	7.0	561
93	Towards automatic patient selection for chemotherapy in colorectal cancer trials. Proceedings of SPIE, 2014, , .	0.8	4
94	EURECCA colorectal: Multidisciplinary Mission statement on better care for patients with colon and rectal cancer in Europe. European Journal of Cancer, 2013, 49, 2784-2790.	2.8	76
95	Accurately Identifying Low-Allelic Fraction Variants in Single Samples with Next-Generation Sequencing: Applications in Tumor Subclone Resolution. Human Mutation, 2013, 34, 1432-1438.	2.5	53
96	Sensitive, Simultaneous Quantitation of Two Unlabeled DNA Targets Using a Magnetic Nanoparticleâ€"Enzyme Sandwich Assay. Analytical Chemistry, 2013, 85, 9238-9244.	6.5	35
97	Role of the Oxidative DNA Damage Repair Gene OGG1 in Colorectal Tumorigenesis. Journal of the National Cancer Institute, 2013, 105, 1249-1253.	6.3	22
98	Virtual reality microscope versus conventional microscope regarding time to diagnosis: an experimental study. Histopathology, 2013, 62, 351-358.	2.9	34
99	KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 39-46.	2.8	26
100	Mutation Detection by Clonal Sequencing of PCR Amplicons and Grouped Read Typing is Applicable to Clinical Diagnostics. Human Mutation, 2013, 34, 248-254.	2.5	8
101	Ultrasensitive single-nucleotide polymorphism detection using target-recycled ligation, strand displacement and enzymatic amplification. Nanoscale, 2013, 5, 5027.	5.6	48
102	Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncology, The, 2013, 14, 749-759.	10.7	333
103	In situ validation of an intestinal stem cell signature in colorectal cancer. Gut, 2013, 62, 1012-1023.	12.1	92
104	Early mortality from colorectal cancer in England: a retrospective observational study of the factors associated with death in the first year after diagnosis. British Journal of Cancer, 2013, 108, 681-685.	6.4	36
105	Chromosome 5q Loss in Colorectal Flat Adenomas. Clinical Cancer Research, 2012, 18, 4560-4569.	7.0	30
106	Prognostic and predictive significance of proliferation in 867 colorectal cancers. Journal of Clinical Pathology, 2012, 65, 989-995.	2.0	9
107	A pictorial description of extralevator abdominoperineal excision for low rectal cancer. Colorectal Disease, 2012, 14, e655-60.	1.4	42
108	Toward Routine Use of 3D Histopathology as a Research Tool. American Journal of Pathology, 2012, 180, 1835-1842.	3.8	128

#	ARTICLE	IF	CITATIONS
109	EnROL: A multicentre randomised trial of conventional versus laparoscopic surgery for colorectal cancer within an enhanced recovery programme. BMC Cancer, 2012, 12, 181.	2.6	35
110	Histopathological Work-Up of Resection Specimens, Local Excisions and Biopsies in Colorectal Cancer. Digestive Diseases, 2012, 30, 2-8.	1.9	21
111	Has the new TNM classification for colorectal cancer improved care?. Nature Reviews Clinical Oncology, 2012, 9, 119-123.	27.6	163
112	Comprehensive Mutation Analysis in Colorectal Flat Adenomas. PLoS ONE, 2012, 7, e41963.	2.5	20
113	T3+ and T4 Rectal Cancer Patients Seem to Benefit From the Addition of Oxaliplatin to the Neoadjuvant Chemoradiation Regimen. Annals of Surgical Oncology, 2012, 19, 392-401.	1.5	24
114	Focus on Extralevator Perineal Dissection in Supine Position for Low Rectal Cancer Has Led to Better Quality of Surgery and Oncologic Outcome. Annals of Surgical Oncology, 2012, 19, 786-793.	1.5	65
115	Comparison of Magnetic Resonance Imaging and Histopathological Response to Chemoradiotherapy in Locally Advanced Rectal Cancer. Annals of Surgical Oncology, 2012, 19, 2842-2852.	1.5	187
116	Understanding Optimal Colonic Cancer Surgery: Comparison of Japanese D3 Resection and European Complete Mesocolic Excision With Central Vascular Ligation. Journal of Clinical Oncology, 2012, 30, 1763-1769.	1.6	352
117	Working at the microscope: analysis of the activities involved in diagnostic pathology. Histopathology, 2012, 60, 504-510.	2.9	11
118	Accuracy of radiological staging in identifying high‐risk colon cancer patients suitable for neoadjuvant chemotherapy: a multicentre experience. Colorectal Disease, 2012, 14, 438-444.	1.4	88
119	An international, multicentre, prospective, randomised, controlled, unblinded, parallel-group trial of robotic-assisted versus standard laparoscopic surgery for the curative treatment of rectal cancer. International Journal of Colorectal Disease, 2012, 27, 233-241.	2.2	250
120	Will Extralevator Abdominoperineal Excision Become the New Gold Standard?. , 2012, , 261-273.		0
121	Value of Mismatch Repair, <i>KRAS</i>, and <i>BRAF</i> Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer. Journal of Clinical Oncology, 2011, 29, 1261-1270.	1.6	593
122	Mesorectal Fascia Instead of Circumferential Resection Margin in Preoperative Staging of Rectal Cancer. Journal of Clinical Oncology, 2011, 29, 2142-2143.	1.6	54
123	MRI Predictive Factors for Long-Term Outcomes of Low Rectal Tumours. Annals of Surgical Oncology, 2011, 18, 3278-3284.	1.5	71
124	Intra-tumoral Heterogeneity of <i>KRAS</i> and <i>BRAF</i> Mutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing. Analytical Cellular Pathology, 2011, 34, 61-66.	1.4	70
125	Preoperative High-resolution Magnetic Resonance Imaging Can Identify Good Prognosis Stage I, II, and III Rectal Cancer Best Managed by Surgery Alone. Annals of Surgery, 2011, 253, 711-719.	4.2	524
126	Can a Novel MRI Staging System for Low Rectal Cancer Aid Surgical Planning?. Diseases of the Colon and Rectum, 2011, 54, 1260-1264.	1.3	47

#	Article	IF	Citations
127	Lymphatic Vessel Distribution in the Mucosa and Submucosa and Potential Implications for T1 Colorectal Tumors. Diseases of the Colon and Rectum, 2011, 54, 35-40.	1.3	40
128	Quality assurance in pathology in colorectal cancer screening and diagnosisâ€"European recommendations. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 458, 1-19.	2.8	127
129	Annex to Quirke et al. Quality assurance in pathology in colorectal cancer screening and diagnosis: annotations of colorectal lesions. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 458, 21-30.	2.8	26
130	Magnetic Resonance Imagingâ€"Detected Tumor Response for Locally Advanced Rectal Cancer Predicts Survival Outcomes: MERCURY Experience. Journal of Clinical Oncology, 2011, 29, 3753-3760.	1.6	557
131	Lymph Nodes, Tumor Deposits, and TNM: Are We Getting Better?. Journal of Clinical Oncology, 2011, 29, 2487-2492.	1.6	120
132	Thirty-day postoperative mortality after colorectal cancer surgery in England. Gut, 2011, 60, 806-813.	12.1	238
133	Validation Study of a Quantitative Multigene Reverse Transcriptaseâ€"Polymerase Chain Reaction Assay for Assessment of Recurrence Risk in Patients With Stage II Colon Cancer. Journal of Clinical Oncology, 2011, 29, 4611-4619.	1.6	341
134	Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. Analytical Cellular Pathology, 2011, 34, 61-6.	1.4	42
135	Improving the Quality of Colon Cancer Surgery Through a Surgical Education Program. Diseases of the Colon and Rectum, 2010, 53, 1594-1603.	1.3	97
136	Patients With Low Rectal Cancer Treated by Abdominoperineal Excision Have Worse Tumors and Higher Involved Margin Rates Compared With Patients Treated by Anterior Resection. Diseases of the Colon and Rectum, 2010, 53, 53-56.	1.3	104
137	Surgical Pathology. , 2010, , 151-164.		0
138	Complete Mesocolic Excision With Central Vascular Ligation Produces an Oncologically Superior Specimen Compared With Standard Surgery for Carcinoma of the Colon. Journal of Clinical Oncology, 2010, 28, 272-278.	1.6	620
139	Evidence-based medicine: the time has come to set standards for staging. Journal of Pathology, 2010, 221, n/a-n/a.	4.5	44
140	Candidate driver genes in focal chromosomal aberrations of stage II colon cancer. Journal of Pathology, 2010, 221, 411-424.	4.5	39
141	High-Resolution Array Comparative Genomic Hybridization in Sporadic and Celiac Diseaseâ€"Related Small Bowel Adenocarcinomas. Clinical Cancer Research, 2010, 16, 1391-1401.	7.0	64
142	Impact of Short-Course Preoperative Radiotherapy for Rectal Cancer on Patients' Quality of Life: Data From the Medical Research Council CR07/National Cancer Institute of Canada Clinical Trials Group C016 Randomized Clinical Trial. Journal of Clinical Oncology, 2010, 28, 4233-4239.	1.6	196
143	Revised Staging: Is It Really Better, or Do We Not Know?. Journal of Clinical Oncology, 2010, 28, e397-e398.	1.6	18
144	A uniform residual tumor (R) classification. Cancer, 2009, 115, 3483-3488.	4.1	194

#	Article	IF	Citations
145	Tracking with virtual slides: a tool to study diagnostic error in histopathology. Histopathology, 2009, 55, 37-45.	2.9	36
146	Virtual reality Powerwall versus conventional microscope for viewing pathology slides: an experimental comparison. Histopathology, 2009, 55, 294-300.	2.9	39
147	MRI staging of low rectal cancer. European Radiology, 2009, 19, 643-650.	4.5	104
148	Association of Molecular Markers With Toxicity Outcomes in a Randomized Trial of Chemotherapy for Advanced Colorectal Cancer: The FOCUS Trial. Journal of Clinical Oncology, 2009, 27, 5519-5528.	1.6	120
149	*KRAS* and *BRAF* Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial. Journal of Clinical Oncology, 2009, 27, 5931-5937.	1.6	517
150	Defining the surgical planes on MRI improves surgery for cancer of the low rectum. Lancet Oncology, The, 2009, 10, 1207-1211.	10.7	66
151	Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet, The, 2009, 373, 811-820.	13.7	1,292
152	Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet, The, 2009, 373, 821-828.	13.7	906
153	Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). Radiotherapy and Oncology, 2009, 92, 148-163.	0.6	275
154	Evidence of the Oncologic Superiority of Cylindrical Abdominoperineal Excision for Low Rectal Cancer. Journal of Clinical Oncology, 2008, 26, 3517-3522.	1.6	376
155	What Is the Role for the Circumferential Margin in the Modern Treatment of Rectal Cancer?. Journal of Clinical Oncology, 2008, 26, 303-312.	1.6	885
156	Pathology grading of colon cancer surgical resection and its association with survival: a retrospective observational study. Lancet Oncology, The, 2008, 9, 857-865.	10.7	375
157	Predictive Biomarkers of Chemotherapy Efficacy in Colorectal Cancer: Results From the UK MRC FOCUS Trial. Journal of Clinical Oncology, 2008, 26, 2690-2698.	1.6	261
158	Molecular markers of chemotherapeutic response and toxicity in colorectal cancer. Expert Review of Anticancer Therapy, 2007, 7, 489-501.	2.4	10
159	Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? The need for high quality pathology. Gut, 2007, 56, 1419-1425.	12.1	109
160	Identifying Stage III Colorectal Cancer Patients: The Influence of the Patient, Surgeon, and Pathologist. Journal of Clinical Oncology, 2007, 25, 2573-2579.	1.6	120
161	Randomized Trial of Laparoscopic-Assisted Resection of Colorectal Carcinoma: 3-Year Results of the UK MRC CLASICC Trial Group. Journal of Clinical Oncology, 2007, 25, 3061-3068.	1.6	1,382
162	Expression of the CUB domain containing protein 1 (CDCP1) gene in colorectal tumour cells. FEBS Letters, 2007, 581, 1137-1142.	2.8	33

#	ARTICLE	IF	CITATIONS
163	The future of the TNM staging system in colorectal cancer: time for a debate?. Lancet Oncology, The, 2007, 8, 651-657.	10.7	148
164	The Site of the Tumor, Not the Type of Operation, Determines the Worse Prognosis of the Low Rectal Cancer. Annals of Surgery, 2006, 244, 331-332.	4.2	0
165	Expression of DNA Double-Strand Break Repair Proteins ATM and BRCA1 Predicts Survival in Colorectal Cancer. Clinical Cancer Research, 2006, 12, 1494-1500.	7.0	71
166	Multimodal Imaging Techniques for the Extraction of Detailed Geometrical and Physiological Information for Use in Multi-Scale Models of Colorectal Cancer and Treatment of Individual Patients. Computational and Mathematical Methods in Medicine, 2006, 7, 177-188.	1.3	8
167	The Modern Abdominoperineal Excision. Annals of Surgery, 2005, 242, 74-82.	4.2	384
168	EphB2 is a Prognostic Factor in Colorectal Cancer. Clinical Cancer Research, 2005, 11, 5181-5187.	7.0	94
169	Low Rectal Cancer: A Call for a Change of Approach in Abdominoperineal Resection. Journal of Clinical Oncology, 2005, 23, 9257-9264.	1.6	546
170	Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. Lancet, The, 2005, 365, 1718-1726.	13.7	2,854
171	The multidisciplinary rectal cancer treatment: Main convergences, controversial aspects and investigational areas which support the need for an European Consensus. Radiotherapy and Oncology, 2005, 76, 241-250.	0.6	48
172	The role of the pathologist. European Journal of Cancer, Supplement, 2005, 3, 351-359.	2.2	2
173	DNA Methylation, a Biomarker for Colorectal Cancer. Annals of the New York Academy of Sciences, 2003, 983, 251-267.	3.8	30
174	Training and quality assurance for rectal cancer: 20 years of data is enough. Lancet Oncology, The, 2003, 4, 695-702.	10.7	148
175	Macroscopic Evaluation of Rectal Cancer Resection Specimen: Clinical Significance of the Pathologist in Quality Control. Journal of Clinical Oncology, 2002, 20, 1729-1734.	1.6	822
176	Rates of Circumferential Resection Margin Involvement Vary Between Surgeons and Predict Outcomes in Rectal Cancer Surgery. Annals of Surgery, 2002, 235, 449-457.	4.2	591
177	Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncology, The, 2002, 3, 75-82.	10.7	85
178	Biology and genetics of colorectal cancer. European Journal of Cancer, 2001, 37, 163-172.	2.8	10
179	Preface to Genomic Pathology - a New Frontier. Journal of Pathology, 2001, 195, 1-2.	4.5	10
180	A comparison of microsatellite instability in early onset gastric carcinomas from relatively low and high incidence European populations. International Journal of Cancer, 2000, 85, 189-191.	5.1	19

#	Article	IF	Citations
181	A comparison of microsatellite instability in early onset gastric carcinomas from relatively low and high incidence European populations. International Journal of Cancer, 2000, 85, 189-191.	5.1	5
182	Preimplantation genetic diagnosis using fluorescent polymerase chain reaction: results and future developments. Journal of Assisted Reproduction and Genetics, 1999, 16, 199-206.	2.5	21
183	Rapid trisomy diagnosis (21, 18, and 13) using fluorescent PCR and short tandem repeats: applications for prenatal diagnosis and preimplantation genetic diagnosis. Journal of Assisted Reproduction and Genetics, 1998, 15, 266-275.	2.5	46
184	Comparison of FISH PRINS, and conventional and fluorescent PCR for single-cell sexing: suitability for preimplantation genetic diagnosis. Journal of Assisted Reproduction and Genetics, 1998, 15, 258-265.	2.5	14
185	Prenatal detection of trisomy 13 from amniotic fluid by quantitative fluorescent polymerase chain reaction. Prenatal Diagnosis, 1998, 18, 669-674.	2.3	12
186	Multiple genetic diagnoses from single cells using multiplex PCR: reliability and allele dropout. , 1998, 18, 1413-1421.		44
187	Experimental models of colorectal cancer. Diseases of the Colon and Rectum, 1998, 41, 490-505.	1.3	31
188	Rapid determination of trisomy 18 parental origin using fluorescent PCR and small tandem repeat markers: case reports. Clinical Genetics, 1998, 53, 92-95.	2.0	5
189	Prenatal detection of trisomy 13 from amniotic fluid by quantitative fluorescent polymerase chain reaction. Prenatal Diagnosis, 1998, 18, 669-674.	2.3	3
190	Assessment of microsatellite alterations in young patients with gastric adenocarcinoma. , 1997, 79, 684-687.		28
191	Fluorescent PCR: A new technique for PGD of sex and single-gene defects. Journal of Assisted Reproduction and Genetics, 1996, 13, 96-103.	2.5	59
192	HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER. , 1996, 179, 129-137.		53
193	Antenatal screening for cystic fibrosis. BJOG: an International Journal of Obstetrics and Gynaecology, 1996, 103, 795-799.	2.3	20
194	HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER. Journal of Pathology, 1996, 179, 129-137.	4.5	8
195	Microsatellite instability in colorectal cancer: Improved assessment using fluorescent polymerase chain reaction. Gastroenterology, 1995, 109, 465-471.	1.3	94
196	The Pathologist's Role in the Assessment of Local Recurrence in Rectal Carcinoma. Surgical Oncology Clinics of North America, 1992, 1, 1-17.	1.5	52
197	Kaposi's Sarcoma: A Clinico-Pathologic Overview. Tumori, 1991, 77, 291-310.	1.1	4
198	Correlation of morphology, immunophenotype, and flow cytometry with remission induction and survival in high grade non-Hodgkin's lymphoma. Journal of Pathology, 1989, 158, 31-39.	4.5	22

#	Article	IF	Citations
199	Further applications of the polymerase chain reaction. Journal of Pathology, 1989, 159, 277-279.	4.5	4
200	Flow cytometry of normal, hyperplastic, and malignant human endometrium. American Journal of Obstetrics and Gynecology, 1989, 161, 487-492.	1.3	17
201	Prognostic significance of DNA aneuploidy and cell proliferation in rectal adenocarcinomas. Journal of Pathology, 1987, 151, 285-291.	4.5	181
202	Congenital Torulopsis glabrata Infection in Man. American Journal of Clinical Pathology, 1980, 73, 137-140.	0.7	16
203	Pathology for the radiologist: pathological insights into colorectal cancer. , 0, , 15-33.		0
204	Relationship Between Baseline Rectal Tumor Length and Magnetic Resonance Tumor Regression Grade Response to Chemoradiotherapy: A Subanalysis of the TRIGGER Feasibility Study. Annals of Surgical Oncology, 0, , .	1.5	1